Citation Impact
Citing Papers
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
2017 Standout
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte
2010 Standout
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
2012 Standout
Routine Bone Marrow Biopsy Has Little or No Therapeutic Consequence for Positron Emission Tomography/Computed Tomography–Staged Treatment-Naive Patients With Hodgkin Lymphoma
2012
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
2008 Standout
Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer
2010 Standout
Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group
2014
Oncological applications of FDG PET imaging: brain tumors, colorectal cancer, lymphoma and melanoma.
1999
Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer
2009 Standout
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging
2006 Standout
Why do cancers have high aerobic glycolysis?
2004 Standout
Nasopharyngeal carcinoma
2005 Standout
The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers
2007
Molecular imaging in drug development
2008 Standout
The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL)
2009
FDG PET for Differentiation of Infection and Aseptic Loosening in Total Hip Replacements: Comparison with Conventional Radiography and Three-Phase Bone Scintigraphy
2004
Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin’s disease
2002
Monitoring response to therapy in cancer using [ 18 F]-2-fluoro-2-deoxy- d -glucose and positron emission tomography: an overview of different analytical methods
2000
Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin’s lymphoma (NHL)
2001
Prevalence and Patterns of Bone Metastases Detected with Positron Emission Tomography Using F-18 FDG
2003
The Future of Cancer Imaging
2002
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
2009 Standout
Paraneoplastic Syndromes Involving the Nervous System
2003 Standout
Phaeochromocytoma
2005 Standout
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin's lymphoma
2004
Head and neck cancer
2008 Standout
Noninvasive Detection of Clinically Occult Lymph-Node Metastases in Prostate Cancer
2003 Standout
The role of positron emission tomography (PET) in the management of lymphoma patients
1999
Value of FDG PET Imaging in the Management of Patients With Thyroid, Neuroendocrine, and Neural Crest Tumors
2004
CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma
2002 Standout
Advances in Biomedical Imaging
2001
Bone marrow involvement in diffuse large B-cell lymphoma: correlation between FDG-PET uptake and type of cellular infiltrate
2008
Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery
2005 Standout
Targeting the phosphoinositide 3-kinase pathway in cancer
2009 Standout
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
2005 Standout
Regulation of cancer cell metabolism
2011 Standout
The impact of fluorodeoxyglucose F 18 positron-emission tomography on the surgical staging of non–small cell lung cancer
2002
FDG-PET/CT predicts outcome in patients with aggressive non-Hodgkin’s lymphoma and Hodgkin’s disease
2006
Cost-effectiveness of FDG-PET for staging non–small cell lung cancer: a decision analysis
1998
Clinical role of positron emission tomography in oncology
2001
Imaging of musculoskeletal infections
2006
Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin’s disease and non-Hodgkin’s lymphoma
2002
Diagnostic Accuracy of 18F-Fluorodeoxyglucose Positron Emission Tomography in the Follow-Up of Papillary or Follicular Thyroid Cancer
2001
Positron emission tomography in the diagnosis and staging of lung cancer: a systematic, quantitative review
2001
Cost-Minimization Analysis of Alternative Diagnostic Approaches in a Modeled Patient With Non-Small Cell Lung Cancer and Subcarinal Lymphadenopathy
2002
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
2015 Standout
18F-FDG PET/CT bone/bone marrow findings in Hodgkin’s lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging
2010
Vertebral Osteomyelitis
2010 Standout
Positron emission tomography with CT in the evaluation of non‐small cell lung cancer in populations with a high prevalence of tuberculosis
2006
Interactions with Aromatic Rings in Chemical and Biological Recognition
2003 Standout
The role of [18F]fluoro-2-deoxyglucose-PET scanning in the diagnosis of paraneoplastic neurological disorders
2001
Neuroblastoma
2007 Standout
CT and 18F-deoxyglucose (FDG) image fusion for optimization of conformal radiotherapy of lung cancers
2001
Tomographic imaging using the nonlinear response of magnetic particles
2005 StandoutNature
18p-FDG PET is superior to67Ga SPECT in the staging of non-Hodgkin’s lymphoma
2004
Accuracy and Clinical Impact of Mediastinal Lymph Node Staging with FDG–PET Imaging in Potentially Resectable Lung Cancer
2000
Astrocyte–endothelial interactions at the blood–brain barrier
2005 Standout
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
2014 Standout
Gallium-67 scintigraphy: a cornerstone in functional imaging of lymphoma
2003
Clinical imaging of cancer metastasis
2000
Metastases from Non-Small Cell Lung Cancer: Mediastinal Staging in the 1990s—Meta-analytic Comparison Of PET and CT
1999
Value of positron emission tomography for lung cancer staging
2002
FDG-PET for diagnosing prosthetic joint infection: systematic review and metaanalysis
2008
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
2008 Standout
Non-Small Cell Lung Cancer: FDG PET for Nodal Staging in Patients with Stage I Disease
2000
Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT results
2000
Positron emission imaging of head and neck cancer, including thyroid carcinoma
2004
Silicosis
2012 Standout
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
2008 Standout
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
2009 Standout
Biologic Correlates of 18Fluorodeoxyglucose Uptake in Human Breast Cancer Measured by Positron Emission Tomography
2002 StandoutNobel
Role of Functional Imaging in the Management of Lymphoma
2011
Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease
2010 Standout
Positron Emission Tomography Scanning: Current and Future Applications
2002
Radionuclide imaging of the painful hip arthroplasty
2005
Intensity of18Fluorodeoxyglucose Uptake in Positron Emission Tomography Distinguishes Between Indolent and Aggressive Non-Hodgkin’s Lymphoma
2005
When, in the context of drug design, can a fluorine atom successfully substitute a hydroxyl group?
2002
Revised Response Criteria for Malignant Lymphoma
2007 Standout
Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease.
2001
Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte
2005 Standout
Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies
2017 StandoutNobel
Endothelial activation, endothelial dysfunction and premature atherosclerosis in systemic autoimmune diseases.
2003
Thoracic positron emission tomography using18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease
2001
Assessment of the Incremental Value of Recombinant Thyrotropin Stimulation before 2-[18F]-Fluoro-2-Deoxy-d -Glucose Positron Emission Tomography/Computed Tomography Imaging to Localize Residual Differentiated Thyroid Cancer
2009
Comparison of fluorine‐18 fluorodeoxyglucose positron emission tomography and Ga‐67 scintigraphy in evaluation of lymphoma
2002
Differentiated Thyroid Cancer: Management of Patients with Radioiodine Nonresponsive Disease
2012
PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.
2002
Functional Imaging of Endocrine Tumors: Role of Positron Emission Tomography
2004
Prognostic Value of Positron Emission Tomography (PET) With Fluorine-18 Fluorodeoxyglucose ([18F]FDG) After First-Line Chemotherapy in Non-Hodgkin’s Lymphoma: Is [18F]FDG-PET a Valid Alternative to Conventional Diagnostic Methods?
2001
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
2014 Standout
Impact of [18F] Fluorodeoxyglucose Positron Emission Tomography on Staging and Management of Early-Stage Follicular Non-Hodgkin Lymphoma
2008
Bone lymphoma: 67Ga scintigraphy and CT for prediction of outcome after treatment.
2002
Diagnosing infection in the failed joint replacement: a comparison of coincidence detection 18F-FDG and 111In-labeled leukocyte/99mTc-sulfur colloid marrow imaging.
2004
Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations
2002 StandoutScience
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
2008 Standout
Prosthetic Joint Infection
2014 Standout
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
2014 Standout
Utility of FDG-PET scanning in lymphoma by WHO classification
2003
2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma
2001
Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
2008
18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis.
2005
Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma.
2006
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
1999 Standout
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
Cost-Minimization Analysis of Alternative Diagnostic Approaches in a Modeled Patient With Non-Small Cell Lung Cancer and Subcarinal Lymphadenopathy
2002
Prognostic value of pretransplantation positron emission tomography using fluorine 18-fluorodeoxyglucose in patients with aggressive lymphoma treated with high-dose chemotherapy and stem cell transplantation
2003
Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)
2007 Standout
Works of Florian Moog being referenced
Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging.
1997
Role of attenuation correction for fluorine-18 fluorodeoxyglucose positron emission tomography in the primary staging of malignant lymphoma
1999
Extranodal malignant lymphoma: detection with FDG PET versus CT.
1998
Positron Emission Tomography for Detection and Staging of Malignant Lymphoma
2000
18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow.
1998
The use of [18F]fluorodeoxyglucose positron emission tomography to differentiate between synovitis, loosening and infection of hip and knee prostheses
2002
Whole-body 2-[18F]-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin’s disease
1998
Lymph node staging in non-small cell lung cancer: evaluation by [18F]FDG positron emission tomography (PET)
1997
FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma.
1999
Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma.
2000